Latest Alemtuzumab Stories
A newer, less expensive drug used to suppress the immune system and prevent organ rejection in kidney and pancreas transplant patients works just as well as its much more expensive counterpart, according to a new study by researchers at Wake Forest University Baptist Medical Center.
The results of these studies will be presented during the American Transplant Congress in Boston, MA May 30 - June 3, 2009 COLUMBIA, Md., May 31 /PRNewswire/ -- The results of two large studies presented by researchers from the Starzl Transplant Institute at the University of Pittsburgh Medical Center demonstrated the long-term safety and efficacy of alemtuzumab induction and tacrolimus monotherapy.
ORLANDO, Fla., May 29 /PRNewswire-FirstCall/ -- GlaxoSmithKline [NYSE: GSK] and Genmab A/S [OMX: GEN] today announced that the United States Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 10 to three that the ARZERRA(TM) (ofatumumab) data are reasonably likely to predict clinical benefit for patients with chronic lymphocytic leukemia (CLL) whose disease is refractory to fludarabine and alemtuzumab.
US drug regulators are carefully scrutinizing a new leukemia drug from pharmaceutical giant GlaxoSmithKline PLC and Genmab to determine whether the medication offers patients enough benefit to sanction its approval.
Three New Studies Initiated in Other Oncology Settings LONDON and COPENHAGEN, Denmark, Jan. 30 /PRNewswire-USNewswire/ -- GlaxoSmithKline (GSK) and Genmab A/S (OMX: GEN) announced today the submission of a Biologics License Application (BLA) to the U.S.
An Agent Showing Improvement in Overall Response Rate Would Earn Higher Patient Share in U.S. Than Europe, According to a New Report from Decision Resources WALTHAM, Mass., Jan.
Data Showed Campath May Lead to Overall Survival in Patients with Poor Prognostic Factors SAN FRANCISCO, Dec. 9 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc.
Data from a pivotal trial suggests that ofatumumab has activity in heavily pre-treated patients who have failed standard treatments PHILADELPHIA, Dec.
WAYNE, N.J., Dec. 5 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc.
A drug developed for patients with leukemia also appears to regenerate brain cells and reverse the effects of relapsing-remitting multiple sclerosis, British researchers said on Wednesday.
- An aromatic woolly plant (Origanum dictamnus) native to Crete, formerly believed to have magical powers.